A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Chalmers, James D ^a   Campling, James ^b   Dicker, Alison ^a   Woodhead, Mark ^c   Madhava, Harish ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Epidemiology; Infection; Mortality; Pneumonia; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ADULT; AGED; ARTICLE; CHRONIC RESPIRATORY TRACT DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; GROUPS BY AGE; HEART DISEASE; HIGH RISK POPULATION; HUMAN; INCIDENCE; META ANALYSIS; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; UNITED KINGDOM; VACCINATION; COST OF ILLNESS; ENGLAND; PNEUMONIA, PNEUMOCOCCAL; WALES;

ADULT; COST OF ILLNESS; ENGLAND; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INCIDENCE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINES, CONJUGATE; WALES;

EID: 84977558593     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0242-0     Document Type: Article

References (67)

1. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144-54.
2. Krone CL, van de Groep K, Trzcinski K, et al. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir Med. 2014;2:141-53.
3. Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-8.
4. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64 Suppl 3:iii1-55.
5. Chalmers JD, Mandal P, Singanayagam A, et al. Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37:1409-20.
6. Chalmers JD, Singanayagam A, Akram AR, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65:878-83.
7. Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis. 2008;14:727-33.
8. Klemets P, Lyytikainen O, Ruutu P, et al. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis. 2008;8:96.
9. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309-16.
10. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68:1057-65.
11. Jiang Y, Gauthier A, Keeping S, et al. Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK. Expert Rev Pharmacoecon Outcomes Res. 2014;14:913-27.
12. Mooney JD, Weir A, McMenamin J, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis. 2008;8:53.
13. Public Health England. Pneumococcal disease: guidance, data and analysis. https://www.gov.uk/government/collections/pneumococcal-disease-guidance-data-and-analysis#epidemiology. Accessed 15 Feb 2016.
14. Hospital Episode Statistics. http://www.hscic.gov.uk/hes. Accessed 15 Feb 2016.
15. Melegaro A, Edmunds WJ, Pebody R, et al. The current burden of pneumococcal disease in England and Wales. J Infect. 2006;52:37-48.
16. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422.
17. Lucero MG, Dulalia VE, Nillos LT et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;CD004977.
18. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114-25.
19. Mangen MJ, Rozenbaum MH, Huijts SM et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=fab1e230-2a90-4c64-8fb0-d948ea4ee5c5&cKey=27e4cf22-da30-4347-997c-d31f6cb1e2ea&mKey=%7B7A574A80-EAB1-4B50-B343-4695DF14907E%7D. Accessed 15 Feb 2016.
20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12.
21. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15:535-43.
22. Chapman KE, Wilson D, Gorton R. Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England. Epidemiol Infect. 2013;141:344-52.
23. Foster D, Knox K, Walker AS, et al. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J Med Microbiol. 2008;57:480-7.
24. Lamb KE, Flasche S, Diggle M, et al. Trends in serotypes and sequence types among cases of invasive pneumococcal disease in Scotland, 1999-2010. Vaccine. 2014;32:4356-63.
25. Kyaw MH, Clarke S, Jones IG, et al. Non-invasive pneumococcal disease and antimicrobial resistance: vaccine implications. Epidemiol Infect. 2002;128:21-7.
26. Inverarity D, Lamb K, Diggle M, et al. Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types. J Med Microbiol. 2011;60:793-802.
27. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10, e1001517.
28. Rodrigo C, Bewick T, Sheppard C, et al. Pneumococcal serotypes in adult non-invasive and invasive pneumonia in relation to child contact and child vaccination status. Thorax. 2014;69:168-73.
29. Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45:1632-41.
30. Rodrigo C, Bewick T, Sheppard C, et al. Clinical features of adults with seven-valent-conjugated-vaccine-serotype pneumococcal pneumonia. Vaccine. 2014;32:1460-5.
31. Sleeman K, Knox K, George R, et al. Invasive pneumococcal disease in England and Wales: vaccination implications. J Infect Dis. 2001;183:239-46.
32. Kyaw MH, Clarke S, Edwards GF, et al. Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies. Epidemiol Infect. 2000;125:561-72.
33. Clarke SC, Scott KJ, McChlery SM. Serotypes and sequence types of pneumococci causing invasive disease in Scotland prior to the introduction of pneumococcal conjugate polysaccharide vaccines. J Clin Microbiol. 2004;42:4449-52.
34. Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802-8.
35. Elston JW, Santaniello-Newton A, Meigh JA, et al. Increasing incidence of invasive pneumococcal disease and pneumonia despite improved vaccination uptake: surveillance in Hull and East Yorkshire, UK, 2002-2009. Epidemiol Infect. 2012;140:1252-66.
36. Farrell DJ, Felmingham D, Shackcloth J, et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother. 2008;62 Suppl 2:ii87-95.
37. Johnson AP, Waight P, Andrews N, et al. Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England. J Infect. 2007;55:394-9.
38. Population estimates for UK, England and Wales, Scotland and Northern Ireland, Mid 2014. http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-and-wales--scotland-and-northern-ireland/mid-2014/index.html.
39. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65:17-24.
40. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med. 2013;30:1412-9.
41. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health. 2012;66:1177-81.
42. Torres A, Blasi F, Dartois N, et al. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70:984-9.
43. Yin Z, Rice BD, Waight P, et al. Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS. 2012;26:87-94.
44. van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS ONE. 2012;7:e39150.
45. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2014 to March 2015. Public Health England, 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448406/hpr2615_ppv.pdf. Accessed 15 Feb 2016.
46. Gladstone RA, Jefferies JM, Faust SN, et al. Continued control of pneumococcal disease in the UK - the impact of vaccination. J Med Microbiol. 2011;60:1-8.
47. van Hoek AJ, Sheppard CL, Andrews NJ, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32:4349-55.
48. Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192:853-8.
49. van Deursen AM, van Mens SP, Sanders EA, et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2012;18:1729-37.
50. Gladstone RA, Jefferies JM, Tocheva AS, et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine. 2015;33:2015-21.
51. Bottomley C, Roca A, Hill PC, et al. A mathematical model of serotype replacement in pneumococcal carriage following vaccination. J Royal Soc Inter Royal Soc. 2013;10:20130786.
52. Choi YH, Jit M, Gay N, et al. 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement? PLoS ONE. 2011;6:e26190.
53. Reynolds R, Mushtaq S, Fry N et al. Expansion of multi-resistant (non-vaccine) serotype 15A in both invasive and respiratory streptococcus pneumoniae infections in the UK and Ireland. ICAAC 2015. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=fab1e230-2a90-4c64-8fb0-d948ea4ee5c5&cKey=27e4cf22-da30-4347-997c-d31f6cb1e2ea&mKey=%7B7A574A80-EAB1-4B50-B343-4695DF14907E%7D. Accessed 15 Feb 2016.
54. Chalmers JD, Rother C, Salih W, et al. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58:330-9.
55. Bafadhel M, Haldar K, Barker B, et al. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J Chron Obstruct Pulmon Dis. 2015;10:1075-83.
56. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186:657-65.
57. Cilloniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J. 2012;40:931-8.
58. Almirall J, Boixeda R, Bolibar I, et al. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med. 2007;101:2168-75.
59. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet. 1987;1:671-4.
60. Akram AR, Chalmers JD, Hill AT. Predicting mortality with severity assessment tools in out-patients with community-acquired pneumonia. QJM. 2011;104:871-9.
61. Eurich DT, Marrie TJ, Minhas-Sandhu JK, et al. Ten-year mortality after community-acquired pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015;192:597-604.
62. Bauer TT, Welte T, Strauss R, et al. Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support? Lung. 2013;191:417-24.
63. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med. 2002;162:1059-64.
64. Mullerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012;106:1124-33.
65. Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM. 2010;103:379-85.
66. Vinogradova Y, Hippisley-Cox J, Coupland C. Identification of new risk factors for pneumonia: population-based case-control study. Br J Gen Pract. 2009;59:e329-38.
67. Millett ER, Quint JK, Smeeth L, et al. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLoS ONE. 2013;8:e75131.